Celestica reported a third-quarter earnings per share (EPS) of $0.11 above expectations and in-line revenues, while guiding its fourth-quarter EPS and revenues in-line. For fiscal year 2025, the company projected EPS above consensus estimates, with revenues also in-line. Skechers announced record-breaking third-quarter sales of $2.35 billion, surpassing earnings expectations by $0.10, although it guided fourth-quarter EPS below consensus while revenues remained in-line. Following this announcement, Skechers' stock surged by 11%. In contrast, Edwards Lifesciences reported a third-quarter EPS that beat estimates by $0.01 but missed on revenues. The company also guided its fourth-quarter EPS and revenues in-line, although it forecasted fourth-quarter sales below Wall Street estimates due to decreased demand and increased competition for its artificial heart valves.